Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and ...

CHICAGO — New research is showing certain weight loss drugs could be linked to eye related issues. A couple studies published in the Journal of the American Medical Association looks into Ozempic, ...

Texas is seeking more than $1 million from Eli Lilly in a lawsuit accusing the drugmaker of persuading physicians to prescribe its medications, including GLP-1s such as Mounjaro and Zepbound, through ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Attorney General Ken Paxton filed a lawsuit this week against Eli Lilly for allegedly bribing Texas health care providers to ...